Clinical trials: Rechallenge
Cancer
Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With Cancer
Very little data are published on the safety of a rechallenge with a BRAF inhibitor or combination of BRAF and MEK inhibitor (BRAFi and MEKi) after an adverse event (AE).
- Trial name
- BRAFREC (NCT05080361)
- Testing
- BRAF inhibitor
- Volunteers
- 16,000 people
- Sponsor
- University Hospital, Caen
Autism
Folate Rechallenge
New evidence suggests that autistic disorder (AD) may be associated with abnormalities in folate metabolism, which is a process that affects genetic expression by facilitating the formation of methyl donors for DNA methylation.
- Trial name
- NCT00672360
- Testing
- Folic acid
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Baylor College of Medicine